

Id : i.m.84c8bdeb6554203aecc19d7d2bd7f19e
CN : SQ1ED01256558
Date : Monday, December 16, 2002 8:00:00 AM GMT
From : Fontana, Patricia
To : McCormack, Eileen
Subject : re: High Dose Seroquel Letter
Attachments :  Doses_above_800mg.doc
Custodians : McCormack, Eileen

From:
Fontana, Patricia


Sent:
Monday, December 16, 2002 10:07 PM

To:
McCormack, Eileen

Subject:
re: High Dose Seroquel Letter

Attachments:
Doses_above_800mg.doc

Hi Eileen,



Here is the final version of the High Dose Seroquel letter. Lucette has reviewed and I incorporated her changes. With respect to the Reinstein abstract, I checked a databases of letters from other countries.

None of them are using the Reinstein abstract in their letters. As previously discussed, John Tumas felt that "referring to it can lead to more questions about it (results, methodology) and would indicate that we support its findings, which we don't" This was considered a sensitive issue. I cut and pasted his comments from previous emails to refresh your memory. Let me know what you think. I am at the BPD preceptorship tomorrow so I will touch base with you Wednesday.

Patricia

Patricia,

The Reinstein/Sonnenberg poster at APA 2001 was a sensitive issue. This was an IIT that we supported, but it was determined that the investigator deviated from the protocol and his results were suspect. There were discussions with the investigator that I was not a part of and it was decided that we would not assist in poster production to try to distance ourselves from the study. Drs. Reinstein and Sonnenberg presented the results anyway, but my understanding is that AZ has chosen to ignore the study.

John

No. Referring to it can lead to more questions about it (results, methodology) and would indicate that we support its findings, which we don't.

Patricia Fontana B.Sc. B.Sc Phm

Medical Information Associate

phone (905) 804-4927

fax (905) 277-3556

email: patricia.fontana@astrazeneca.com